In the first half of July 2022, 13 new procedure codes were introduced by the Code Service of the Finnish National Health and Wellbeing Institution (THL). The introduced codes are dedicated to diagnostic imaging, surgical procedures, radiology, and some other fields.

The Scottish Health Technologies Group (SHTG) is a national health technology assessment (HTA) agency providing advice to NHSScotland on using new and existing health technologies, likely to significantly impact healthcare. In July 2022, SHTG published three reports (KardiaMobile for detecting atrial fibrillation, complex endovascular aneurysm repair, and Togetherall platform). Currently, the SHTG is working on assessments of technologies in the field of cancer, radiotherapy, musculoskeletal diseases, transplantation, and other topics.

The French National Authority for Health released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies in July 2022. Twenty recommendations were published in relation to the registration, modification of registration conditions, and renewal of registration for devices in the List of reimbursable products and services. Opinions concern cardiovascular and peripheral vascular, neurovascular and neuromodulation, orthopedic, endocrine, and ENT devices, as well as breast implants and medical aids. Except for this, CNEDiMTS published two positive and two negative opinions concerning transitional coverage of devices.

In July 2022, the National Institute for Health and Care Excellence (NICE) published two new Interventional Procedure Guidance (transcatheter tricuspid valve annuloplasty for tricuspid regurgitation, and transcatheter tricuspid valve leaflet repair for tricuspid regurgitation), one new Diagnostic Guidance (PLGF-based testing to help diagnose suspected preterm pre-eclampsia), and four new Medtech Innovation Briefings (ProciseDx point-of-care platform for IBD, RespiraSense for continuously monitoring respiratory rate, Lenus COPD Support Service, and cyanoacrylate glue for hernia mesh fixation). Also, five clinical guidelines were updated.

In May-July 2022, two more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers.

In July 2022, the Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) published on its website five Digi-HTAs in the fields of eHealth and in-vitro diagnostics.

In July 2022, Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV) announced the extension of temporary reimbursement for gene expression profile (GEP) testing for early-stage breast cancer detection until December 31, 2022, and for molecular biology tests by next-generation sequencing (NGS) until June 30, 2023.

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With regional decree 13241 of July 4, 2022, Tuscany Regional Healthcare has published assessments of three medical devices in the cardiovascular area.

On June 27, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) published the determined funding priorities for healthcare research projects (seven topics) and clinical guidelines (four topics).

In July 2022, NHS Accelerated Access Collaborative launched a new NHS Innovation Service to support the spread of promising and impactful innovations. It is an online service for health innovators (individuals and companies) providing tailored and coordinated support or advice for "adoption-ready" products. The service will help innovators to understand the regulations and standards they need to meet, the evidence they should demonstrate, and the NHS procurement and reimbursement processes.

On July 5, 2022, it was announced by the Ministry of Health that the Council of Ministers authorized the tender for the purchase of ten units of equipment for the treatment with proton therapy and associated electromedical equipment for an estimated value of €271 million (VAT included).

On June 24, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) published the decisions, recommending the transfer to standard care for two completed projects. The projects relate to preventing delirium, postoperative cognitive dysfunction, and back pain therapy using e-health.